← Back to patent-cliff list
克拉霉素
Tier C — Watch / tradeClarithromycin
Taisho Pharmaceutical Holdings Co Ltd
Originator
1991
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：50S ribosomal subunit
Brand：Naxy、Klaricid、Macladin、Klacid、Biaxin、Clarino-500、Clarimax、Cyllind、Clarith、Veclam、Biaxin XL、Minebase
Indications (approved)：鼻窦炎、扁桃体炎、急性支气管炎、慢性支气管炎、下呼吸道感染、咽炎、传染性疾病、肺炎
Regional status
US
临床二期
1999-11-02
EU
临床三期
2000-04-01
China
批准上市
1996-01-01
Japan
批准上市
1991-03-29
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Clarithromycin?
Approved indications include: 鼻窦炎, 扁桃体炎, 急性支气管炎, 慢性支气管炎, 下呼吸道感染, 咽炎, 传染性疾病, 肺炎.
When does the Clarithromycin patent expire?
No public expiry year is available for Clarithromycin yet; this page updates once verified.
How do I get a quote for Clarithromycin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25